{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:56:40Z","timestamp":1790693800069,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH SBIR","award":["#AI052670"],"award-info":[{"award-number":["#AI052670"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.vaccine.2009.10.111","type":"journal-article","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T09:12:36Z","timestamp":1257498756000},"page":"1056-1061","source":"Crossref","is-referenced-by-count":52,"title":["Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques"],"prefix":"10.1016","volume":"28","author":[{"given":"Brian D.","family":"Livingston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Ellefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Hannaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.10.111_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1146\/annurev.immunol.15.1.617","article-title":"DNA vaccines","volume":"15","author":"Donnelly","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.10.111_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.1874","article-title":"Rational design of gene-based vaccines","volume":"208","author":"Barouch","year":"2006","journal-title":"J Pathol"},{"issue":"9653","key":"10.1016\/j.vaccine.2009.10.111_bib4","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.111_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2008.0212","article-title":"Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults","volume":"25","author":"Harro","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.2.2.2620","article-title":"Preclinical and clinical safety studies on DNA vaccines","volume":"2","author":"Schalk","year":"2006","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.6.2.227","article-title":"Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells","volume":"6","author":"Tsen","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.111_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/14760584.4.3.315","article-title":"Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens","volume":"4","author":"Pavlenko","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/104454904322759902","article-title":"Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination","volume":"23","author":"Nagata","year":"2004","journal-title":"DNA Cell Biol"},{"issue":"18","key":"10.1016\/j.vaccine.2009.10.111_bib10","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2009.02.061","article-title":"DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial","volume":"27","author":"Jones","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2009.10.111_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/CVI.00492-07","article-title":"Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy","volume":"15","author":"Wilson","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2007.10.061","article-title":"Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults","volume":"26","author":"Gorse","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/14760584.7.2.175","article-title":"Current progress of DNA vaccine studies in humans","volume":"7","author":"Lu","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2009.10.111_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0020-7519(03)00056-0","article-title":"Technical and regulatory hurdles for DNA vaccines","volume":"33","author":"Donnelly","year":"2003","journal-title":"Int J Parasitol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.10.111_bib15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14712598.7.11.1647","article-title":"Electroporation-based DNA immunisation: translation to the clinic","volume":"7","author":"Luxembourg","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2009.10.111_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","article-title":"DNA vaccines: developing new strategies to enhance immune responses","volume":"42","author":"Abdulhaqq","year":"2008","journal-title":"Immunol Res"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.vaccine.2007.10.066","article-title":"Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation","volume":"26","author":"LeBlanc","year":"2008","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2009.10.111_bib18","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2005.08.014","article-title":"Enhancement of immune responses to an HBV DNA vaccine by electroporation","volume":"24","author":"Luxembourg","year":"2006","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2009.10.111_bib19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1586\/14760584.7.7.1085","article-title":"DNA vaccination and gene therapy: optimization and delivery for cancer therapy","volume":"7","author":"Bodles-Brakhop","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"21","key":"10.1016\/j.vaccine.2009.10.111_bib20","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1016\/j.vaccine.2005.08.017","article-title":"Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation","volume":"24","author":"Otten","year":"2006","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2009.10.111_bib21","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1073\/pnas.0806901105","article-title":"A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses","volume":"105","author":"Chen","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"40","key":"10.1016\/j.vaccine.2009.10.111_bib22","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1016\/j.vaccine.2008.03.090","article-title":"Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation","volume":"26","author":"Rosati","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2009.10.111_bib23","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1128\/JVI.00055-07","article-title":"Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques","volume":"81","author":"Luckay","year":"2007","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.10.111_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00063030-200519040-00003","article-title":"Anthrax vaccines: a development update","volume":"19","author":"Little","year":"2005","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.111_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2672.2006.03112.x","article-title":"Past, imminent and future human medical countermeasures for anthrax","volume":"101","author":"Baillie","year":"2006","journal-title":"J Appl Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14787210.7.2.219","article-title":"Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis","volume":"7","author":"Tournier","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.111_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/523578","article-title":"Vaccines: countering anthrax: vaccines and immunoglobulins","volume":"46","author":"Grabenstein","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2009.10.111_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.5.4.417","article-title":"Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine","volume":"5","author":"Keitel","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"33\u201334","key":"10.1016\/j.vaccine.2009.10.111_bib29","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.111_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"issue":"40","key":"10.1016\/j.vaccine.2009.10.111_bib31","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.vaccine.2008.03.064","article-title":"Potentiation of an anthrax DNA vaccine with electroporation","volume":"26","author":"Luxembourg","year":"2008","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2009.10.111_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2009.10.111_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2009.10.111_bib34","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1128\/IAI.00792-06","article-title":"Protective antigen as a correlative marker for anthrax in animal models","volume":"74","author":"Kobiler","year":"2006","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.111_bib35","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"issue":"32","key":"10.1016\/j.vaccine.2009.10.111_bib36","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2009.10.111_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.111_bib38","doi-asserted-by":"crossref","DOI":"10.4161\/hv.5.8.8725","article-title":"Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults","volume":"5","author":"Keitel","year":"2009","journal-title":"Hum Vaccin"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.111_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/IAI.00788-08","article-title":"Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies","volume":"77","author":"Nguyen","year":"2009","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2009.10.111_bib40","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1128\/IAI.68.10.5731-5734.2000","article-title":"Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis","volume":"68","author":"Brossier","year":"2000","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.111_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CVI.00321-07","article-title":"Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor","volume":"15","author":"Taft","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.111_bib42","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/IAI.01254-08","article-title":"Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed","volume":"77","author":"Reason","year":"2009","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2009.10.111_bib43","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect Immun"},{"issue":"37","key":"10.1016\/j.vaccine.2009.10.111_bib44","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"10.1016\/j.vaccine.2009.10.111_bib45","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2009.03.058","article-title":"A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A","volume":"27","author":"Gardiner","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.111_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.vaccine.2003.09.020","article-title":"Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen","volume":"22","author":"Garmory","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.111_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1471-4906(02)02259-7","article-title":"Of mice and men: species variations of Toll-like receptor expression","volume":"23","author":"Rehli","year":"2002","journal-title":"Trends Immunol"},{"issue":"43","key":"10.1016\/j.vaccine.2009.10.111_bib48","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2008.07.093","article-title":"Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle","volume":"26","author":"van Drunen Littel-van den Hurk","year":"2008","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2009.10.111_bib49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0264-410X(02)00574-1","article-title":"Induction of immune responses by DNA vaccines in large animals","volume":"21","author":"Babiuk","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.111_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2006.11.063","article-title":"PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice","volume":"331","author":"Ribeiro","year":"2007","journal-title":"Int J Pharm"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09016624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09016624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T14:51:30Z","timestamp":1544885490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09016624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0264410X09016624"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.111","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}